Loss of transgene following ex vivo gene transfer is associated with a dominant Th2 response: Implications for cutaneous gene therapy

Molecular Therapy

Volumn 15, Issue 5, 2007, Pages 954-961

  Lu, Zhenmei ^a   Ghazizadeh, Soosan ^a,b  

^a Columbia University ^*  (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GREEN FLUORESCENT PROTEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 5 ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL TRANSPLANTATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; EOSINOPHIL; EX VIVO GENE TRANSFER; GENE EXPRESSION; GRAFT REJECTION; IMMUNE RESPONSE; IN VIVO GENE TRANSFER; INFLAMMATORY INFILTRATE; INTERMETHOD COMPARISON; KERATINOCYTE; MOUSE; NONHUMAN; TH2 CELL; TRANSGENE; VIRAL GENE DELIVERY SYSTEM;

ADOPTIVE TRANSFER; ANIMALS; CELLS, CULTURED; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EOSINOPHILS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GREEN FLUORESCENT PROTEINS; IMMUNOGLOBULIN G; INTERLEUKIN-4; INTERLEUKIN-5; KERATINOCYTES; MICE; RETROVIRIDAE; SKIN; TH2 CELLS; TRANSGENES;

MUS;

EID: 34247239206     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.sj.6300086     Document Type: Article

References (40)

1. Ghazizadeh, S, Katz, AB, Harrington, R and Taichman, LB (2004). Lentivirus-mediated gene transfer to human epidermis. J Invest Dermatol Symp Proc 9: 269-275.
2. Serrano, F, Del Rio, M, Larcher, F, Garcia, M, Munoz, E and Escarnez, MJ et al. (2003). A comparison of targeting performance of oncoretroviral versus lentiviral vectors on human keratinocytes. Hum Gene Ther 14: 1579-1585.
3. Dellambra, E, Pellegrini, G, Guerra, L, Ferrari, G, Zambruno, G and Mavilio, F et al. (2000). Toward epidermal stem cell-mediated ex vivo gene therapy of junctional epidermolysis bullosa. Hum Gene Ther 11: 2283-2287.
4. Ghazizadeh, S, Kalish, RS and Taichman, LB (2003). Immune-mediated loss of transgene expression in skin: Implications for cutaneous gene therapy. Mol Ther 7: 296-303.
5. Lu, Z and Ghazlzadeh, S (2005). Host immune responses in ex vivo approaches to cutaneous gene therapy targeted to keratinocytes. Exp Dermatol 14: 727-735.
6. Brown, BD and Lillicrap, D (2002). Dangerous liaisons: The role of "danger" signals in the immune response to gene therapy. Blood 100: 1133-1140.
7. Song, ES, Lee, V, Surh, CD, Lynn, A, Brumm, D and Jolly, DJ et al. (1997). Antigen presentation in retroviral vector-mediated gene transfer in vivo. Proc Natl Acad Sci USA 94: 1943-1948.
8. Cho, JH, Youn, JW and Sung, YC (2001). Cross-priming as a predominant mechanism for inducing CD8(+) T cell responses in gene gun DNA immunization. J Immunol 167: 5549-5557.
9. Heath, WR and Carbone, FR (2001). Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol 19: 47-64.
10. Anderson, CC, Carroll, JM, Gallucci, S, Ridge, JP, Cheever, AW and Matzinger, P (2001). Testing time-, ignorance-, and danger-based models of tolerance. J Immunol 166: 3663-3671.
11. Pasare, C and Medzhitov, R (2005). Toll-like receptors: Linking innate and adaptive immunity. Adv Exp Med Biol 560: 11-18.
12. Ferrari, S, Pellegrini, G, Mavilio, F and De Luca, M (2005). Gene therapy approaches for epidermolysis bullosa. Clin Dermatol 23 430-436.
13. Matzinger, P (1994). Tolerance, danger, and the extended family. Annu Rev Immunol 12: 991-1045.
14. Heath, WR, Belz, GT, Behrens, GM, Smith, CM, Forehan, SP and Parish, IA et al. (2004). Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol Rev 199 9-26.
15. Rocha, PN, Plumb, TJ, Crowley, SD and Coffman, TM (2003). Effector mechanisms in transplant rejection. Immunol Rev 196: 51-64.
16. Yang, Y, Ertl, HC and Wilson, JM (1994). MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1 433-442.
17. Tripathy, SK, Black HB, Goldwasser, E and Leiden, JM (1996). Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat Med 2: 545-550.
18. Le Moine, A, Goldman, M and Abramowicz, D (2002). Multiple pathways to allograft rejection. Transplant 73: 1373-1381.
19. Le Moine, A and Goldman, M (2003). Non-classical pathways of cell-mediated allograft rejection: New challenges for tolerance induction? Am J Transplant 3: 101-106.
20. Ghazizadeh, S, Doumeng, C and Taichman, LB (2002). Durable and stratum-specific gene expression in epidermis. Gene Ther 9: 1278-1285.
21. Abbas, AK and Janeway Jr, CA (2000). Immunology: Improving on nature in the twenty-first century. Cell 100: 129-138.
22. Paul, WE and Seder, RA (1994). Lymphocyte responses and cytokines. Cell 76: 241-251.
23. Sanderson, CJ (1992). Interleukin-5, eosinophils, and disease. Blood 79: 3101-3109
24. Garlisi, CG, Kung, TT, Wang, P, Minnicozzi, M, Umland, SP and Chapman, RW et al. (1999). Effects of chronic anti-interleukin-5 monoclonal antibody treatment in a murine model of pulmonary inflammation. Am J Respir Cell Mol Biol 20: 248-255.
25. Schowalter, DB, Meuse, L, Wilson, CB, Linsley, PS and Kay, MA (1997). Constitutive expression of murine CTLA41g from a recombinant adenovirus vector results in prolonged transgene expression. Gene Ther 4 853-860.
26. Dobrzynski, E, Fitzgerald, JC, Cao, O, Mingozzi, F, Wang, L and Herzog, RW (2006). Prevention of cytotoxic T lymphocyte responses to factor IX-expressing hepatocytes by gene transfer-induced regulatory T cells. Proc Natl Acad Sci USA 103: 4592-4597.
27. Herzog, RW and Dobrzynski, E (2004). Immune implications of gene therapy for hemophilia. Semin Thromb Hemost 30: 215-226.
28. Sanderson, CJ (1988). Interleukin-5: An eosinophil growth and activation factor. Dev Biol Stand 69: 23-29.
29. Braun, MY, Desalle, F, Le Moine, A, Pretolani, M, Matthys, P and Kiss, R et al. (2000). IL-5 and eosinophils mediate the rejection of fully histoincompatible vascularized cardiac allografts: Regulatory role of alloreactive CD8(+) T lymphocytes and IFN-gamma. Eur J Immunol 30: 1290-1296.
30. Le Moine, A, Flamand, V, Demoor, FX, Noel, JC, Surquin, M and Kiss, R et al. (1999). Critical roles for IL-4, IL-5, and eosinophils in chronic skin allograft rejection. J Clin Invest 103: 1659-1667.
31. Surquin, M, Le Moine, A, Flamand, V, Nagy, N, Rombaut, K and Demoor, FX et al. (2002). Skin graft rejection elicited by β2-microglobulin as a minor transplantation antigen involves multiple effector pathways: role of fas-fas ligand interactions and Th2-dependent graft eosinophil infiltrates. J Immunol 169: 500-506.
32. Agnello, D, Lankford, CS, Bream, J, Morinobu, A, Gadina, M and O'Shea, JJ et al. (2003). Cytokines and transcription factors that regulate T helper cell differentiation: New players and new insights. J Clin Immunol 23: 147-161.
33. Li, M, Hener, P, Zhang, Z, Kato, S, Metzger, D and Chambon, P (2006). Topical vitamin D3 and low-calcemic analogs induce thymic stromal lymphopoietin in mouse keratinocytes and trigger an atopic dermatitis. Proc Natl Acad Sci USA 103: 11736-11741.
34. Soumelis, V, Reche, PA, Kanzler, H, Yuan, W, Edward, G and Homey, B et al. (2002). Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol 3: 673-680.
35. Kishimoto, K, Dong, VM, Issazadeh, S, Fedoseyeva, EV, Waaga, AM and Yamada, A et al. (2000). The role of CD154-CD40 versus CD28-B7 costimulatory pathways in regulating allogeneic Th1 and Th2 responses in vivo. J Clin Invest 106: 63-72.
36. Hadjantonakis, AK, Gertsenstein, M, Ikawa, M, Okabe, M and Nagy, A (1998). Generating green fluorescent mice by germline transmission of green fluorescent ES cells. Mech Dev 76: 79-90.
37. Oliva Jr, AA, Jiang, M, Lam, T, Smith, KL and Swann, JW (2000). Novel hippocampal interneuronal subtypes identified using transgenic mice that express green fluorescent protein in GABAergic interneurons. J Neurosci 20: 3354-3368.
38. Kinsella, TM and Nolan, GP (1996). Episomal vectors rapidly and stably produce high-titer recombinant retrovirus. Hum Gene Ther 7: 1405-1413.
39. Lei, J, Cheng, J, Li, Y, Li, S and Zhang, L (2005). CD80, but not CD86, express on cultured murine keratinocyte stem cells. Transplant Proc 37: 289-291.
40. Ghazizadeh, S, Harrington, R and Taichman, LB (1999). in vivo transduction of mouse epidermis with recombinant retroviral vectors: implications for cutaneous gene therapy. Gene Ther 6: 1267-1275.